Umeclidinium Bromide And Vilanterol Trifenatate has 5 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Monoamine Oxidase Inhibitors (Maois), Nonselective Beta-Adrenergic Antagonists, Andthiazide. Patients taking Umeclidinium Bromide And Vilanterol Trifenatate should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 5
- Major
- 2
- Moderate
- 3
Major (2)
- Umeclidinium Bromide And Vilanterol Trifenatate + Monoamine Oxidase Inhibitors (Maois)— Use with extreme caution. May potentiate vilanterol's effect on cardiovascular system, increasing risk of adverse cardia…
- Umeclidinium Bromide And Vilanterol Trifenatate + Nonselective Beta-Adrenergic Antagonists— May block bronchodilatory effects of vilanterol and produce severe bronchospasm in COPD patients. Avoid use; if necessar…
Moderate (3)
- Umeclidinium Bromide And Vilanterol Trifenatate + Andthiazide— May worsen electrocardiographic changes and/or hypokalemia associated with non-potassium-sparing diuretics when combined…
- Umeclidinium Bromide And Vilanterol Trifenatate + Ketoconazole— 7 DRUG INTERACTIONS • Strong cytochrome P450 3A4 inhibitors (e.g., ketoconazole): Use with caution. Concomitant administ…
- Umeclidinium Bromide And Vilanterol Trifenatate + Loop Diuretics— May worsen electrocardiographic changes and/or hypokalemia associated with non-potassium-sparing diuretics when combined…